This is my second shot on OCGN and still a similar analysis.
OCGN
is still a relatively small market cap that can grow very quickly. Covaxin, their covid vaccine candidate is still waiting for FDA approval. Occugen is partenering with an indian company -Bharat Biotech and have a deal with them to market Covaxin in the U.S. The vaccine is already commercialized in a couple of countries, eg. India, Mexico, the Phillippines.. OCGN will be in charge of commercializing the vaccine in the US if it's approved. The vaccine phase 3 tests showed very good results, it achieved an overall efficacy of 78% and a 100% efficacy against severe covid19. With the J&J vaccine being put on hold, Covaxin has a key role to play. Any rumours or confirmed news about the FDA approval, will send the stock above 30$.
OCGN
is still a relatively small market cap that can grow very quickly. Covaxin, their covid vaccine candidate is still waiting for FDA approval. Occugen is partenering with an indian company -Bharat Biotech and have a deal with them to market Covaxin in the U.S. The vaccine is already commercialized in a couple of countries, eg. India, Mexico, the Phillippines.. OCGN will be in charge of commercializing the vaccine in the US if it's approved. The vaccine phase 3 tests showed very good results, it achieved an overall efficacy of 78% and a 100% efficacy against severe covid19. With the J&J vaccine being put on hold, Covaxin has a key role to play. Any rumours or confirmed news about the FDA approval, will send the stock above 30$. 